β‐Cell secretory defects are present in pancreatic insufficient cystic fibrosis with 1‐hour oral glucose tolerance test glucose ≥155 mg/dL
Sign Up to like & getrecommendations! Published in 2018 at "Pediatric Diabetes"
DOI: 10.1111/pedi.12700
Abstract: Patients with pancreatic insufficient cystic fibrosis (PI‐CF) meeting standard criteria for normal glucose tolerance display impaired β‐cell secretory capacity and early‐phase insulin secretion defects. We sought evidence of impaired β‐cell secretory capacity, a measure of… read more here.
Keywords: glucose tolerance; cell secretory; pancreatic insufficient; insufficient cystic ... See more keywords
1783-P: Effects of DPP-4 Inhibition on the Enteroinsular Axis in Pancreatic Insufficient Cystic Fibrosis
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes"
DOI: 10.2337/db20-1783-p
Abstract: Impaired incretin secretion may contribute to insulin secretion defects in pancreatic insufficient cystic fibrosis (PI-CF). We hypothesized that dipeptidyl peptidase-4 (DPP-4) inhibitor therapy would increase glucagon-like peptide-1 (GLP-1) and improve insulin secretion in glucose intolerant… read more here.
Keywords: cystic fibrosis; pancreatic insufficient; merck inc; insufficient cystic ... See more keywords